Myriad Genetics Board Member Daniel Skovronsky Resigns, Citing No Disagreements
MYGN sits 29% above its 52-week low of $3.53.
Summary
Daniel M. Skovronsky has resigned from Myriad Genetics' Board of Directors, effective June 17, 2026. This news follows an 8-K filing today disclosing the change. The company explicitly stated the resignation was not due to any disagreement with its operations or policies. While the departure is noted as amicable, any change in board composition is a governance event for a company that recently reported a wider net loss in Q1 2026.
At the time of this announcement, MYGN was trading at $4.55 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $425M. The 52-week trading range was $3.53 to $8.59. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Wiseek News.